ViewRay, Inc. (OTCQB: VRAY) is a publically held company that develops advanced radiation therapy technology for the treatment of cancer. The MRIdian® system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient’s anatomy.

Funding: OrbiMed Advisors, Fidelity Biosciences, Kearny Venture Partners, Aisling Capital, Siemens Venture Capital, Cowealth Medical Holding Company, JumpStart, Montrose Capital, Xeraya Capital

Stage: Commercial

News: ViewRay Receives Japanese Regulatory Approval for MRIdian Linac System,ViewRay to Raise $59 Million Through Sale of Stock and Warrants